Phase II pilot randomised, factorial, short term dose escalation, open label, blinded
intermediary endpoint trial, in two hospital centres in the UK, of tolerability and safety of
cilostazol, isosorbide mononitrate, both or neither in patients with small vessel disease
manifest as symptomatic small subcortical stroke.